Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...
An investigational treatment for acromegaly -- also known as gigantism -- was safe and boosted biochemical control, according to final topline findings of the phase III ACROINNOVA 2 study. Meeting the ...
On Track To Initiate Pivotal Trial Of Octreolin TM (An Oral Form Of Octreotide Acetate) In Patients With Acromegaly By Year End 2010 NEW YORK and JERUSALEM, June 14 /PRNewswire/ -- Chiasma, Inc., a ...
Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...
Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...
An open-label, multicenter, randomized phase II study of atezolizumab and bevacizumab with Y90 TARE in patients with unresectable hepatocellular carcinoma (HCC). Background: Somatostatin receptor ...
CAM2029 is an investigational ready-to-use, long-acting octreotide subcutaneous injection depot. Polycystic liver disease is a rare genetic disorder characterized by the progressive growth of more ...
LUND, Sweden, April 25, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results